• Test Code:
    4815
  • Department:
    Solid Tumors
  • Test Synonyms:
    Nanostring protein assay • Vantage 3D Solid Tumor Panel • Phospho-protein panel
  • CPT Code(s):
    81479
Background:

***Only Availalbe as a Research Test***

This test is based on Nanostring’s Vantage 3D Protein Solid Tumor Panel (FFPE), which consists of a cocktail of 25 oligonucleotide-tagged antibodies designed to bind to key proteins involved in intracellular signaling or to specific sites of phosphorylation on these proteins (see table below). The panel includes non-specific mouse IgG1 and rabbit IgG antibodies as controls for background binding (total of 27 antibodies). Samples of FFPE cancer cell lines are included in each run, which serve as controls for antibody performance and for inter-run data normalization.


The panel is validated only for core biopsies of breast cancer or prostate cancer. Other samples types, including excisional biopsies and resections, are not acceptable for this assay due to the known lability of protein phosphorylation. Results are reported relative to a cohort of previously analyzed solid tumors that match the pathologic diagnosis of the submitted sample.

4E-BP1

Phospho-MEK1/2

EGF Receptor

Phospho-PDK1

GSK-3B

Phospho-PRAS40

HER2

Phospho-S6 Ribosomal Protein

Ki-67

Phospho-c-Raf

Met

Phospho-p44/42 MAPK ERK 1/2

Pan-Akt

Progesterone Receptor

Pan-Keratin

S6 Ribosomal Protein

Phospho-4E-BP1

p44/42 MAPK ERK1/2

Phospho-AMPKa

P53

Phospho-Akt

Histone H3

Phospho-EGF Receptor

MmAb-IgG1

Phospho-GSK-3B

RbAb-IgG

Phospho-Histone H3

 

Methodology:

  1. Microscopic examination of the specimen to confirm presence of adequate tumor
  2. Overnight binding of oligonucleotide-tagged antibody cocktail
  3. UV-release of oligonucleotides
  4. Detection/counting of oligonucleotides using Nanostring MAX nCounter

Specimen Requirements:

  • Only core biopsy specimens are acceptable.
  • 1 paraffin block or 2 unstained sections of tumor (4-5 microns).
  • If shipping materials are needed, contact Client Services at (855) 535-1522.
A REQUISITION FORM MUST ACCOMPANY ALL SAMPLES.  Please include detailed clinical information.

Test Performed (Days):

Mon-Fri

Turn Around Time:

7-10 days

Shipment Sensitivity Requirements:

References:

Additional Info:

Contact Us
Innovations in Testing
View All Tests

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More